PDF
Full
Outline
To analyze the application effect of the intelligent management system for clinical trial drugs.
Based on the overall architecture established for the intelligent module and the management of experimental drugs, we compared the error rates of monthly prescriptions and recovery forms from 2024 to 2025, as well as the error rates of annual prescriptions and recovery forms from 2024 to 2025.
The prescription error rates for January 2024 and 2025 were 33.33% (4 prescriptions/12 prescriptions) and 0% (0 prescriptions/19 prescriptions), respectively; for May, they were 30.00% (6 prescriptions/20 prescriptions) and 5.56% (2 prescriptions/36 prescriptions), respectively; for June, they were 36.00% (9 prescriptions/25 prescriptions) and 3.21% (6 prescriptions/187 prescriptions), respectively; for July, they were 23.91% (11 prescriptions/46 prescriptions) and 5.14% (9 prescriptions/175 prescriptions), respectively; for August, they were 10.71% (6 prescriptions/56 prescriptions) and 1.82% (3 prescriptions/165 prescriptions), respectively; for September, they were 10.20% (10 prescriptions/98 prescriptions) and 2.84% (5 prescriptions/176 prescriptions), respectively; for October, they were 13.21% (7 prescriptions/53 prescriptions) and 2.70% (2 prescriptions/74 prescriptions), respectively; for December, they were 12.50% (6 prescriptions/48 prescriptions) and 3.02% (13 prescriptions/430 prescriptions), respectively. The above indicators were statistically significant differences between the two groups (P<0.05, P<0.01). The prescription error rates for the years 2024-2025 were 12.41% (82 prescriptions/661 prescriptions) and 3.38% (60 prescriptions/1 777 prescriptions), respectively, showing a downward trend, and there were statistically significant differences between the two groups(P<0.000 1). The overall error rate of the collected forms decreased, but differences were not statistically significant (P>0.05).
The intelligent management system can improve the efficiency and accuracy of drug management, and it is recommended to further optimize the recovery process.
PDF
120
28
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62199257
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
